Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat(®) Inhaler in Patients with Chronic Obstructive Pulmonary Disease.

Aalbers, René ; Maleki-Yazdi, M Reza ; Hamilton, Alan ; Waitere-Wijker, Stella ; Zhao, Yihua ; Amatto, Valeria C ; Schmidt, Olaf and Bjermer, Leif LU (2015) In Advances in Therapy 32(9). p.809-822
Abstract
Combining long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) is beneficial in chronic obstructive pulmonary disease (COPD), as the two classes of bronchodilator have complementary modes of action. The optimal dose for the fixed-dose combination of the LAMA tiotropium and the LABA olodaterol needed to be determined. In this phase II trial, the dose response of tiotropium on top of olodaterol was investigated in a free-dose combination, while other phase II studies have explored different doses of olodaterol on top of tiotropium, with both drugs delivered using the Respimat(®) inhaler.
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Advances in Therapy
volume
32
issue
9
pages
809 - 822
publisher
Adis
external identifiers
  • pmid:26404912
  • wos:000362902000002
  • scopus:84944048093
  • pmid:26404912
ISSN
0741-238X
DOI
10.1007/s12325-015-0239-8
language
English
LU publication?
yes
id
c70ef57e-8852-4170-91f7-44e7c594484d (old id 8035015)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26404912?dopt=Abstract
date added to LUP
2016-04-01 10:54:19
date last changed
2025-01-14 01:49:26
@article{c70ef57e-8852-4170-91f7-44e7c594484d,
  abstract     = {{Combining long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) is beneficial in chronic obstructive pulmonary disease (COPD), as the two classes of bronchodilator have complementary modes of action. The optimal dose for the fixed-dose combination of the LAMA tiotropium and the LABA olodaterol needed to be determined. In this phase II trial, the dose response of tiotropium on top of olodaterol was investigated in a free-dose combination, while other phase II studies have explored different doses of olodaterol on top of tiotropium, with both drugs delivered using the Respimat(®) inhaler.}},
  author       = {{Aalbers, René and Maleki-Yazdi, M Reza and Hamilton, Alan and Waitere-Wijker, Stella and Zhao, Yihua and Amatto, Valeria C and Schmidt, Olaf and Bjermer, Leif}},
  issn         = {{0741-238X}},
  language     = {{eng}},
  number       = {{9}},
  pages        = {{809--822}},
  publisher    = {{Adis}},
  series       = {{Advances in Therapy}},
  title        = {{Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat(®) Inhaler in Patients with Chronic Obstructive Pulmonary Disease.}},
  url          = {{http://dx.doi.org/10.1007/s12325-015-0239-8}},
  doi          = {{10.1007/s12325-015-0239-8}},
  volume       = {{32}},
  year         = {{2015}},
}